Dr. Edmund Y. Ting Joins Pressure BioSciences, Inc. as Senior Vice President of Engineering.

WEST BRIDGEWATER, Mass. -- Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that Edmund Y. Ting, Sc.D. has joined the Company as its Senior Vice President of Engineering. In this role, Dr. Ting will be responsible for directing the Company's engineering efforts in the design and development of all instruments and disposables for its core Pressure Cycling Technology (PCT) program.

Dr. Ting is a recognized expert in the field of high pressure component and systems engineering. Prior to joining PBI, Dr. Ting served as the Chief Research Officer of Avure Technologies, a leading worldwide manufacturer of high pressure hydrostatic processing equipment for the food and materials processing industry, where he worked from 2001 to 2006. From 1990 to 2001, Dr. Ting was employed by Flow International Corporation, a world leader in the ultrahigh pressure waterjet cutting technology market, and the parent company of Avure until November 2005. Dr. Ting last held the position of VP of Engineering Research and Development at Flow, before moving over to Avure in 2001. Dr. Ting earned a Bachelor of Science degree in mechanical engineering from Northeastern University and a Science Doctorate in materials science and engineering from the Massachusetts Institute of Technology.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "Over the past few months, we have been successful in filling the very important positions of Chief Financial Officer, VP of Marketing & Business Development, and Director of Research and Development with individuals whom we consider to be extraordinary managers. The addition of Dr. Ting as Senior VP of Engineering adds yet another excellent member to our formidable, senior management team. We now have all key senior management positions filled for the first time in our short history as PBI. We also have a strong patent position, and have placed or sold PCT Sample Preparation Systems into the laboratories of a number of industry thought leaders throughout the United States. We are seeing the initial emergence of scientific publications and presentations by independent researchers that are citing the features and benefits of PCT. We are beginning to receive name recognition as a company, there are a growing number of potential customers, and we have access to sufficient cash to meet our short and mid-term goals. These are truly very exciting times for Pressure BioSciences."

Dr. Ting commented: "We see an existing and growing market for robust, versatile, and user-friendly sample preparation systems to fill a variety of needs in the genomic and proteomic fields. To that end, it is our plan to design and develop a wide range of PCT-based instruments, from simple, hand-held devices to elaborate, high throughput, fully automated machines. In addition to sample preparation, it is also our goal to become a worldwide leader in the use of high pressure technology in many other important areas of the life sciences. I am both excited and pleased to have the opportunity to work with the talented and hard-working staff that has now been assembled to help our Company achieve these goals."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's expectations about the future. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: uncertainties inherent in the development of new products, including the Company's new Bench Top PCT instrument, including technical risks, cost overruns, and manufacturing and other delays; the risk that the Company may be unable to successfully develop new sample preparation systems that address the needs of the genomic, proteomic, or other life science markets, or that these markets may not materialize as anticipated by the Company; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the risk that the Company's products will not achieve market acceptance; the risk that the Company will not be able to increase demand or sales for its products; the risk that the Company will be unable to attract and retain qualified personnel; the risk that the hiring of Dr. Ting may not benefit the Company; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2005 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com.